VivoSeq
Oncology

Non-Small Cell Lung Cancer

1.4K

Pipeline Programs↗

665

Active Trials↗

318

Companies Involved↗

Non-Small Cell Lung Cancer is a highly competitive landscape with 1352 programs across 318 companies. The most active players are TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics), Active Biotech AB, MediLink Therapeutics (Suzhou) Co., Ltd.. 40 therapies are approved with 268 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

100/100

Pipeline Velocity

96/100

Mech. Concentration

4/100

Completion Rate

69/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

2 programs

Phase 1A

Active Biotech AB

1 program

Phase 1M

MediLink Therapeutics (Suzhou) Co., Ltd.

1 program

Phase 1K

Kyowa Kirin, Inc.

1 program

Phase 1T

TILT Biotherapeutics Ltd.

1 program

Phase 1X

Xuanzhu Biopharmaceutical Co., Ltd.

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical71

Tremelimumab

AstraZeneca

Dacomitinib

Pfizer

Nedaplatin

Jiangsu Simcere Pharmaceutical Co., Ltd.

Tegafur

The First Affiliated Hospital with Nanjing Medical University

Necitumumab

Eli Lilly

Phase 1247

Gilteritinib

Astellas

Theophylline

Pfizer

Midazolam

Conrado Roberto Hoffmann Filho

Mobocertinib

Takeda

Regorafenib

Bayer

Phase 2726

Epcoritamab

Genmab

Sotorasib

Amgen

RAS(ON) Multi Inhibitor

Revolution Medicines

Cabozantinib

Bristol-Myers Squibb

Trastuzumab

Organon and Co

Phase 3268

Osimertinib

AstraZeneca

Pembrolizumab

Merck & Co.

Nivolumab

Bristol-Myers Squibb

Atezolizumab

Roche

Datopotamab Deruxtecan

Daiichi Sankyo

Approved40

Pirtobrutinib

Eli Lilly

Larotrectinib

Bayer

Methotrexate

Alnylam Pharmaceuticals

Propofol

Fresenius Kabi Oncology Ltd.

Vinorelbine

Pierre Fabre Medicament

Analysis

Modality Breakdown

86%

Small molecule

1,274 of 1,486 classified programs — the dominant modality here.

14%ALL OTHERSMonoclonal antibody1329%Vaccine232%Protein / enzyme211%Cell therapy13<1%Antibody–drug conjugate10<1%RNA therapy5<1%Other8<1%

Small molecule leads; the ring shows all 1,486 classified programs, each share of the total. Modality classified for 99% of 1,640 pipeline programs.

Analysis

Trial Status

2,636

clinical trials

Completed1,123 · 43%
Terminated378 · 14%
Unknown status345 · 13%
Recruiting317 · 12%
Active, not recruiting220 · 8%
Not yet recruiting124 · 5%
Other129 · 5%

Clinical Trials

Trial Activity

2636 trials

Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer
Recruiting·HHebei Medical University Fourth Hospital·Phase 2·NCT05241028·80 enrolled
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Recruiting·AbbVie logoAbbVie·Phase 3·NCT04928846·698 enrolled
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)
Recruiting·GSK logoGSK·Phase 1/2·NCT06405230·40 enrolled
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
Recruiting·PPierre Fabre Medicament·Phase 1/2·NCT06043817·251 enrolled
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
Recruiting·—·Phase 1/2·NCT04691817·28 enrolled
A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 1/2·NCT05949606·160 enrolled
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
Recruiting·Regeneron logoRegeneron·Phase 1/2·NCT04077099·231 enrolled
Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers, and HMBD-001 + Cetuximab in Advanced Squamous Cell Cancers
Recruiting·HHummingbird Bioscience·Phase 1/2·NCT05910827·98 enrolled
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer
Recruiting·Shanghai Hengrui Pharmaceutical Co., Ltd. logoShanghai Hengrui Pharmaceutical Co., Ltd.·Phase 1/2·NCT06512051·248 enrolled
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
Recruiting·—·Phase 1/2·NCT06071013·20 enrolled
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
Recruiting·VVA Office of Research and Development·Phase 1/2·NCT05467748·66 enrolled
A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation
Recruiting·HHenan Genuine Biotech Co., Ltd.·Phase 1/2·NCT07231068·153 enrolled
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Recruiting·Merck & Co. logoMerck & Co.·Phase 1/2·NCT07286149·190 enrolled
Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer
Recruiting·MMayo Clinic·Phase 2·NCT06918132·60 enrolled
Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer
Recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT07410975·54 enrolled
Page 1 of 176

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)